Bio-Techne Corporation (TECH)

62,66 -0,86 (-1,35%) Börsenschluss: 04:00PM EDT

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854
https://www.bio-techne.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 3.200

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Kim Kelderman	CEO, President & Director	845,71k	126,84k	1968
Mr. James T. Hippel	Executive VP of Finance & CFO	691,78k	N/A	1971
Mr. Shane Bohnen	Senior VP, General Counsel & Corporate Secretary	353,6k	N/A	1975
Mr. Charles R. Kummeth	Senior Advisor	1,26M	48,58M	1960
Mr. William A. Geist	President of Protein Sciences Segment	533,67k	N/A	1970
Dr. Gary J. Latham Ph.D.	VP & CTO	N/A	N/A	N/A
David Clair	Senior Director of Investor Relations & Corporate Development	N/A	N/A	N/A
Mr. Gerry Andros	Vice President of Sales and Marketing	N/A	N/A	N/A
Mr. Robert M. Gavin	Vice President of Corporate Development	724,51k	N/A	1968
Ms. Brenda S. Everson	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Bio-Techne Corporations ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 4, Shareholderrechte: 1, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.